Artelo Biosciences, Inc.
ARTL
$1.04
$0.010.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -233.75% | 53.47% | 2.01% | 19.20% | -25.48% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.29% | 24.19% | 7.83% | 85.48% | -6.06% |
| Change in Net Operating Assets | 417.50% | -18.70% | 142.86% | -238.31% | -28.57% |
| Cash from Operations | -229.95% | 62.29% | 29.88% | -13.33% | -44.06% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -88.24% | 142.86% | 37.90% | -53.70% | 249.62% |
| Cash from Investing | -88.24% | 142.86% | 37.90% | -53.70% | 249.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | 71.88% | -94.02% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -100.00% | 71.88% | -94.02% |
| Foreign Exchange rate Adjustments | -325.00% | 500.00% | 50.00% | -100.00% | -105.26% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -158.08% | 1,207.01% | 80.62% | -1,020.45% | 105.71% |